Treatment of Peptic Ulcer Disease and Nonulcer Dyspepsia

Journal of Family Practice, July, 2001 by Linda N. Meurer

[10.] Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282:1929-933.

[11.] Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95:1681-690.

[12.] Veldhuyzen van Zanten SJ, Flook N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Can Med Assoc J 2000; 162(suppl 12):S3-S23.

[13.] Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Raffalo S, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000: 160:1285-291.

[14.] Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244-252.

[15.] Laine L, Hopkins RJ, Girardi L. Has the impact of Helicobacter priori therapy on ulcer recurrence in the Unites States been overstated? A meta-analysis of rigourously designed trials. Amer J Gastroenterol 1998; 93:1409-415.

[16.] Megraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999; 11(suppl 2):S35-S37.

[17.] Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter priori with triple therapy. Gastroenterology 1992; 102:493-96.

[18.] Rene W.M., van der Hulst RWM, Keller JJ, Rauws EA, Tytgat G. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1:6-18.

[19.] Graham D Y. Highlights from 100th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week. Helicobacter Today 1999; 6:1-24.

[20.] Laine L, Estrada R, Trujillo M, Emami S. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. Am J Gastroenterol 1997; 92:2213-215.

[21.] De Wit NJ, Quartero AO, Numans ME. Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case-finding in general practice. Aliment Pharmacol Ther 1999; 13:1317-321.

[22.] Wong BC, Lam SK, Lai KC, et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 1999; 13:303-09.

[23.] Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998; 129:547-50.

[24.] Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for nonulcer dyspepsia. Cochrane Database of Systematic Reviews 2001; Issue 1.

[25.] Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis [see comments]. BMJ 1999; 319:1040-44.